Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer
Barlow LJ, Benson MC. Curr Urol Rep. 2013 Apr;14(2):65-70. doi: 10.1007/s11934-013-0312-2.


Department of Urology, Herbert Irving Comprehensive Cancer Center, Herbert Irving Pavilion, Columbia University Medical Center, 11th Floor 161 Fort Washington Ave., New York, NY, 10032, USA, ljb2119@columbia.edu.


The definitive treatment for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who fail to respond to intravesical bacillus Calmette-Guérin (BCG) is cystectomy. However, many patients who experience recurrence after BCG are either poor operative candidates or refuse surgery due to the long-term impact on their quality of life. In the last decade, there has been an increased interest in alternative intravesical therapies, and several novel chemotherapeutics have emerged as promising agents for high-risk NMIBC patients unable or unwilling to undergo cystectomy. Additionally, extended treatment regimens with combined induction and maintenance therapy have been investigated, and may increase the durability of response to these new agents, as has been shown for conventional intravesical therapy.